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Long-Term Survival Analysis of Intraperitoneal versus 
Intravenous Chemotherapy for Primary Ovarian Cancer and 
Comparison between Carboplatin- and Cisplatin-based 
Intraperitoneal Chemotherapy
In epithelial ovarian cancer (EOC), intraperitoneal (IP) administration of chemotherapy is an 
effective first-line treatment and may improve outcomes, compared with intravenous (IV) 
chemotherapy. We used Kaplan-Meier survival analysis to compare long-term survival 
between propensity score-matched patients with advanced EOC receiving IP (n = 34) vs. IV 
(n = 68) chemotherapy. Additionally, clinical features associated with carboplatin-based 
(n = 21) and cisplatin-based (n = 16) IP chemotherapy were analyzed and compared with 
those associated with IV chemotherapy. The IP and IV chemotherapy groups had a median 
follow-up duration of 67 (range, 3–131) and 62 (range, 0–126) months, respectively, with 
no significant difference in progression-free survival (PFS) (P = 0.735) and overall survival 
(OS) (P = 0.776). A significantly higher proportion of patients in the IV (91.2%) than in the 
IP (67.6%) chemotherapy group (P = 0.004) received ≥ 6 cycles. However, the frequency 
of toxic events (anemia, granulocytopenia, nausea/vomiting, abdominal pain, 
hepatotoxicity, neuromuscular effects) was significantly higher in the IP than in the IV 
group. Within the IP group, no significant differences were observed in PFS (P = 0.533) 
and OS (P = 0.210) between the cisplatin-based and carboplatin-based chemotherapy 
subgroups. The 10-year OS was 28.6% and 49.2% in carboplatin-based and cisplatin-
based IP chemotherapy groups, respectively. Toxic events (granulocytopenia, leukopenia, 
nausea/vomiting, abdominal pain, hepatotoxicity, neuromuscular effects) were 
significantly more common in the cisplatin-based subgroup. In patients with EOC, 
cisplatin-based IP chemotherapy may be an acceptable alternative to IV chemotherapy 
regarding long-term survival, but toxicity must be addressed.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the most common cause of 
cancer-associated death among women with gynecologic can-
cers (1,2). The current standard therapy for patients with ad-
vanced stage EOC consists of cytoreductive surgery and adju-
vant combination chemotherapy with platinum and a taxane 
(3,4). Intraperitoneal (IP) administration of chemotherapy for 
EOC is effective as first-line treatment. Compared with stan-
dard IV treatment, IP chemotherapy was recently demonstrat-
ed in three large randomized phase III trials (5-7) to improve 
outcomes; a Cochrane meta-analysis confirmed these findings 
(8).
 Given the toxicity associated with cisplatin-based IP chemo-
therapy and the emerging data on IP carboplatin administra-
tion from nonrandomized studies (9-12), we substituted carbo-
platin for cisplatin in IP chemotherapy and investigated the fea-
sibility of this regimen (13). Few studies supporting the long-
term efficacy or oncologic outcomes of carboplatin-based IP 
chemotherapy have been conducted during the last decade 
(10,14), although randomized data to support the selection of 
an IP or IV regimen will soon be available from the GOG 252 
(ClinicalTrials.gov identifier, NCT00951496) and OV21/PET-
ROC (ClinicalTrials.gov identifier, NCT00993655) trials.
 The purpose of this study was to compare the long-term sur-
vival of propensity score-matched advanced EOC patients treat-
ed with either IP or intravenous (IV) chemotherapy. Also, as a 
subgroup analysis, we compared the long-term outcomes among 
IP chemotherapy-treated patients according to chemotherapy 
regimens; carboplatin-based or cisplatin-based.
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MATERIALS AND METHODS
Study design
Patients diagnosed with EOC and treated with IV or IP chemo-
therapy after cytoreductive surgery between January 2006 and 
December 2008, were included consecutively. Patients who re-
ceived neoadjuvant chemotherapy before debulking surgery 
were excluded. A gynecologic oncology team at a single insti-
tute conducted all of the procedures, and a dedicated radiolo-
gist and pathologists at the same institute reviewed all data from 
the imaging studies and pathologic specimens, respectively. A 
retrospective chart review was performed to collect clinical and 
pathologic data. All patients were staged according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO) crite-
ria for ovarian cancer.
 The subjects in IP chemotherapy group received either 1) IP 
carboplatin area under curve (AUC) 5 on day 1, IV paclitaxel 175 
mg/m2 on day 2, and IP paclitaxel 60 mg/m2 on day 8 or 2) IV 
paclitaxel 135 mg/m2 on day 1, IP cisplatin 100 mg/m2 on day 2, 
and IP paclitaxel 60 mg/m2 on day 8. Standard premedication 
was administered to prevent hypersensitivity reactions to pacli-
taxel, and hydration and antiemetic agents were administered 
before the administration of carboplatin. Before the IP infusion 
of chemotherapeutic agents, 500 mL of warm normal saline was 
infused through the peritoneal port. For the IP infusion, carbo-
platin or paclitaxel was reconstituted in 1 L of warm normal sa-
line and infused as rapidly as possible through the port. After IP 
administration of the chemotherapeutic agents, 500 mL of warm 
normal saline was infused through the peritoneal port, followed 
by rolling the patient into 4 different positions every 15 minutes 
to disperse the drug throughout the peritoneal cavity. This series 
of treatments was performed every 3 weeks. For IP access, 31 
BardPort catheters and 6 Tenckhoff catheters were used. Bard-
Port implantable port is an access device designed to provide 
repeated access to IP infusion, and Tenckhoff catheter a cuffed 
silicone catheter that is permanently inserted into the abdomi-
nal cavity for infusion of solution (15,16). Patients, who were de-
termined to stop IP chemotherapy due to toxic effects, under-
went sequential IV chemotherapy up to 6 to 8 cycles totally.
 Routine follow-up was performed every 3 months, compris-
ing a clinical examination and measurement of serum carbo-
hydrate antigen 125 levels, and radiologic investigations when 
indicated. Recurrence and progression were evaluated using 
the Response Evaluation Criteria in Solid Tumors Committee 
(RECIST) (17). All toxicities were graded according to the Na-
tional Cancer Institute’s Common Toxicity Criteria for Adverse 
Events (NCI CTCAE) version 4.0 (18). Specifically, grade 3 he-
matologic toxic effects were defined as follows: anemia, hemo-
globin < 8 g/dL; granulocytopenia, < 1,000 granulocytes/mm3; 
leukopenia, < 2,000 white cells/mm3; and thrombocytopenia, 
< 50,000 platelets/mm3. Grade 2 toxic effects were defined as 
follows: abdominal pain, pain relieved by oral opioids; fever, 
temperature > 38°C; tinnitus, moderate symptoms of tinnitus; 
hearing loss, ability to hear normal levels of voice and sound 
but not whispered sounds; neuromuscular effects, absence of 
deep tendon reflexes, weakness, and peripheral nerve pain; 
and pulmonary effects, transient dyspnea on mild exertion. IP 
port issues included infection, blockage, leakage, and peritone-
al irritation by the catheter.
 We used Kaplan-Meier survival analysis to compare long-term 
survival between 1:2 propensity score-matched patients with 
advanced EOC treated with either IP or IV chemotherapy. Ad-
ditionally, clinical features associated with carboplatin-based 
or cisplatin-based IP chemotherapy were analyzed and com-
pared with those associated with IV chemotherapy, during the 
whole course of chemotherapy.
Statistical analysis
IBM SPSS version 23 for Windows (IBM Corp., Armonk, NY, USA) 
was used for the statistical analysis. The Kolmogorov-Smirnov 
test was used to verify standard normal distribution assump-
tions. Pearson’s chi-square, Fisher’s exact, and Mann-Whitney 
U tests were used in the univariate analysis. To reduce the effect 
of selection bias and potential confounding in this retrospective 
cohort study, estimated propensity scores were used to match 
the IP group to IV group. In our study, this was computed for 
each of the patients using a logistic regression model including 
the following variables: age, FIGO stage, tumor histology, tu-
mor grade, and residual disease. The propensity score model 
was well-calibrated (Hosmer-Lemeshow goodness-of-fit test, 
P = 0.987). Based on the propensity scores, 34 patients who un-
derwent IP chemotherapy were matched to 68 patients who 
underwent IV chemotherapy. Progression-free survival (PFS) 
and overall survival (OS) for patients with stage 3 or 4 cancer 
were compared between the chemotherapy regimens using 
Kaplan-Meier survival analyses. A P value < 0.05 was consid-
ered statistically significant.
Ethics statement
The protocol received Institutional Review Board approval of 
the Yonsei University College of Medicine (IRB No. 4-2017-0031) 
and was performed in accordance with the ethical standards 
described in the Declaration of Helsinki. The requirement to 
obtain a written informed consent was waived by the Institu-
tional Review Board of the Yonsei University College of Medi-
cine because our study was retrospective research based on med-
ical records, and this research presented no more than minimal 
risk of harm to subjects.
RESULTS
Flowchart of patient selection is presented in Fig. 1. The clinico-
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Fig. 1. Flowchart of patient selection. 
EOC = epithelial ovarian cancer, pts = patients, PDS = primary debulking surgery, 
NAC = neoadjuvant chemotherapy, CTx = chemotherapy, IP = intraperitoneal, IV = 
intravenous.
Consecutive 202 EOC pts (2006-2008)
158 EOC pts who received PDS
IP CTx : 37 pts
• Carboplatin-based : 21 pts
• Cisplatin-based : 16 pts
IP CTx : 34 pts
• Carboplatin-based : 18 pts
• Cisplatin-based : 16 pts
IV CTx : 121 pts
IV CTx : 68 pts
44 pts who received NAC 
were excluded
Route of CTx
Propensity score matching
Table 1. Characteristics of patients in the IP and IV chemotherapy groups before and after propensity score matching
P atient characteristics
Before matching After matching
IP chemotherapy (n = 37)
IV chemother-
apy (n = 121)
P value SD
IP chemotherapy 
(n = 34)
IV chemotherapy 
(n = 68)
P value SDCarboplatin 
(n = 21)
Cisplatin 
(n = 16)
P value
Median age, yr 53 (37–72) 52 (41–65) 0.844 58 (22–82) 0.325 0.287 52.5 (37–72) 65.5 (43–71) 0.604 1.185
FIGO stage 0.453 0.001 0.718
   IA 1 (4.8) 0 0 - 0 0 -
   IC 1 (4.8) 0 0 - 0 0 -
   IIIC 17 (81.0) 15 (93.8) 84 (69.4) 0.571 33 (97.1) 65 (95.6) 0.232
   IV 0 1 (6.2) 37 (30.6) 1.524 1 (2.9) 3 (4.4) 0.232
   Recurrent 2 (9.5) 0 - - - - -
Histology 0.145 0.292 0.804
   Serous 16 (76.2) 14 (87.5) 95 (78.5) 0.088 29 (85.3) 61 (89.7) 0.224
   Mucinous 0 0 8 (6.6) - 0 0 -
   Endometrioid 1 (4.8) 2 (12.5) 6 (5.0) 0.290 3 (8.8) 4 (5.9) 0.241
   Clear cell 4 (19.0) 0 5 (4.1) 0.570 2 (5.9) 3 (4.4) 0.167
Tumor grade 0.258 0.879 0.853
   Grade 1 3 (14.3) 0 7 (5.8) 0.200 3 (8.8) 4 (5.9) 0.241
   Grade 2 7 (33.3) 5 (31.2) 40 (33.1) 0.016 11 (32.4) 22 (32.4) 0
   Grade 3 11 (52.4) 11 (68.8) 74 (61.2) 0.039 20 (58.8) 42 (61.8) 0.069
Residual disease 0.788 0.080 0.972
   NGR 4 (19.0) 2 (12.5) 31 (25.6) 0.318 4 (11.8) 8 (11.8) 0
  < 1.0 cm 15 (71.4) 13 (81.3) 67 (55.4) 0.507 27 (79.4) 53 (77.9) 0.048
  ≥ 1.0 cm 2 (9.5) 1 (6.2) 23 (19.0) 0.539 3 (8.8) 7 (10.3) 0.094
IP access 0.592 - -
   BardPort catheter 17 (81.0) 14 (87.5) - - 28 (82.4) - -
   Tenckhoff catheter 4 (19.0) 2 (12.5) - - 6 (17.6) - -
Values are presented as median (range) or number (%).
IP = intraperitoneal, IV = intravenous, SD = standardized difference, FIGO = International Federation of Gynecology and Obstetrics, NGR = no gross residual disease.  
pathologic characteristics of the IP (unmatched, n = 37; matched, 
n = 34) and IV (unmatched, n = 121; matched, n = 68) chemo-
therapy groups are listed in Table 1. The median durations of 
follow-up were 67 (range, 3–131) and 62 (range, 0–126) months 
for patients receiving IP and IV chemotherapy, respectively. 
Within the IP group, the median durations of follow-up were 52 
(range, 16–131) and 96 (range, 3–126) months for carboplatin- 
and cisplatin-based IP chemotherapy subgroups, respectively.
 A description of the chemotherapy regimens is shown in Ta-
ble 2. Adjuvant carboplatin- and cisplatin-based IP chemother-
apy regimens were initiated 11.0 days and 9.5 days after prima-
ry staging surgery, respectively (P = 0.790). Notably, the num-
ber of total chemotherapy cycles was greater (P = 0.021) and 
the proportion of patients who received ≥ 6 cycles was higher 
in the carboplatin-based than in the cisplatin-based IP chemo-
therapy subgroup (P = 0.049). Compared with the entire IP che-
motherapy group, the IV chemotherapy group had a significant-
ly higher proportion (91.2%) of patients who received ≥ 6 cy-
cles of chemotherapy (P = 0.004). Peritoneal recurrence was 
less likely to occur in IP chemotherapy group, compared with 
IV chemotherapy group (P = 0.002), even though the overall re-
current rate was not significantly different (P = 0.816).
 The frequency of toxic events related to IP and IV chemother-
apy are summarized in Table 3. Patients undergoing cisplatin-
based IP chemotherapy experienced more non-hematogenous 
toxicities than those treated with carboplatin-based IP chemo-
therapy: A significantly greater proportion of patients in the cis-
platin-based IP chemotherapy group experienced grade 3 gran-
ulocytopenia (56.2% vs. 23.8%, P = 0.044) and leukopenia (62.5% 
vs. 23.8%, P = 0.018). Patients treated with cisplatin-based IP 
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chemotherapy were also more likely than those treated with car-
boplatin-based IP chemotherapy to experience chemotherapy-
related grade 2 or 3 nausea/vomiting (75.0% vs. 19.0%, P = 0.001), 
abdominal pain (62.5% vs. 23.8%, P = 0.018), hepatotoxicity 
(43.8% vs. 9.5%, P = 0.016), and neuromuscular effects (56.2% 
vs. 19.0%, P = 0.019). One patient who received cisplatin-based 
IP chemotherapy died after completion of 5 cycles of chemo-
therapy because of chemotherapy-related toxicity. Twelve pa-
tients (32.4%) experienced IP port-related complications, pri-
marily port malfunction/obstruction and 1 case of catheter-re-
lated bowel irritation. Port-related complications necessitated 
discontinuation of IP chemotherapy in 4 patients. Compared to 
the entire IP chemotherapy group, the IV chemotherapy group 
had a significantly lower proportion of patients who experienced 
the following toxic events: anemia (P = 0.002), granulocytope-
nia (P = 0.034), nausea/vomiting (P < 0.001), abdominal pain 
(P < 0.001), hepatotoxicity (P < 0.001), and neuromuscular ef-
fects (P < 0.001).
 The Kaplan-Meier survival analysis showed no significant 
difference in PFS (P = 0.735, Fig. 2A) and OS (P = 0.776, Fig. 2B) 
between the IP and IV chemotherapy groups. The 10-year PFS 
was 26.4% and 20% in the IP and IV groups, respectively, while 
the 10-year OS was 38.0% and 33.5% in IP and IV groups, respec-
tively. Moreover, within the IP chemotherapy group, there was 
no statistically significant difference in PFS (P = 0.533, Fig. 3A) 
and OS (P = 0.210, Fig. 3B) between the carboplatin-based and 
cisplatin-based IP chemotherapy subgroups: The 10-year PFS 
was 24.1% and 40.0% and the 10-year OS was 28.6% and 49.2% in 
carboplatin-based and cisplatin-based IP chemotherapy groups, 
respectively.
Table 2. Description of chemotherapy-related outcomes in propensity score-matched EOC patients by route of infusion, and by IP chemotherapy regimen
Variables
IP chemotherapy IV chemotherapy 
(n = 68)
P value
IP carboplatin (n = 18) IP cisplatin (n = 16) P value
Median time to initiation of from date of surgery  
   chemotherapy, day 
11 (7–18) 9.5 (8–33) 0.790 10 (8–33) 0.165
Median No. of chemotherapy cycles 6 (1–9) 5.5 (1–9) 0.021 6 (2–9) 0.216
No. of cycles completed
   1 1 (5.9) 1 (6.3) - 0 -
   2 0 2 (12.5) - 1 (1.5) -
   3 1 (5.9) 0 - 1 (1.5) -
   4 1 (5.9) 2 (12.5) - 1 (1.5) -
   5 0 3 (18.8) - 3 (4.4) -
  ≥ 6 15 (83.3) 8 (50.0) 0.049 62 (91.2) 0.004
Recurrence 15 (83.3) 9 (56.3) 0.489 50 (73.5) 0.816
   Peritoneal recurrence 7 (38.9) 4 (25.0) 0.916 42 (61.8) 0.002
Values are presented as number (range) or number (%).
EOC = epithelial ovarian cancer, IP = intraperitoneal, IV = intravenous. 
Table 3. Frequency of hematologic toxic effects ( ≥  grade 3) and other toxic effects (≥ grade 2) during any course of treatment in patients with FIGO stage IIIC or IV ovarian 
cancer, by chemotherapy regimen
Toxic effects
IP chemotherapy IV chemotherapy 
(n = 68)
P value
IP carboplatin (n = 21) IP cisplatin (n = 16) P value
Hematologic toxic effect
   Anemia (hemoglobin < 8.0 g/dL) 8 (38.1) 10 (62.5) 0.141 15 (22.1) 0.002
   Granulocytopenia ( < 1,000 granulocytes/mm3) 5 (23.8) 9 (56.2) 0.044 43 (63.2) 0.034
   Leukopenia ( < 2,000 white cells/mm3) 5 (23.8) 10 (62.5) 0.018 29 (42.6) 0.888
   Thrombocytopenia ( < 50,000 platelets/mm3) 4 (19.0) 5 (31.2) 0.391 17 (25.0) 0.872
Non-hematologic toxic effect
   Nausea/vomiting 4 (19.0) 12 (75.0) 0.001 3 (4.4) < 0.001
   Abdominal pain 5 (23.8) 10 (62.5) 0.018 5 (7.4) < 0.001
   Hepatotoxicity 2 (9.5) 7 (43.8) 0.016 0 < 0.001
   Fever 5 (23.8) 2 (12.5) 0.384 12 (17.6) 1.000
   Neuromuscular effects 4 (19.0) 9 (56.2) 0.019 1 < 0.001
   Tinnitus 0 1 (6.2) 0.245 0 0.155
   Hearing loss 0 0 1 0 1.000
   Pulmonary effects 0 0 1 0 1.000
   IP port issues 8 (38.1) 4 (25.0) 0.399 - -
FIGO = International Federation of Gynecology and Obstetrics, IP = intraperitoneal, IV = intravenous.
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DISCUSSION
The present study demonstrated that carboplatin-based IP che-
motherapy may be an acceptable alternative to cisplatin-based 
IP chemotherapy or conventional IV chemotherapy for the man-
agement of patients with advanced EOC in terms of long-term 
survival, although the toxicity of IP-based chemotherapy re-
mains a problem. However, the lower frequency of toxic events 
observed with carboplatin-compared with cisplatin-based IP 
chemotherapy appears to be a key element allowing for com-
pletion of the planned ≥ 6 cycles of chemotherapy; this is a pri-
mary factor for a favorable long-term survival outcome (19).
 The underlying principle of IP chemotherapy is the ability to 
deliver high concentrations of the appropriate chemotherapeu-
tic agent to the site where most recurrences are likely to devel-
op, after performing complete cytoreduction. Despite the Na-
tional Cancer Institute (NCI) Clinical Announcement that was 
based on multiple trials showing level-1 evidence for a survival 
benefit (20), IP chemotherapy has not been widely adopted in 
the management of ovarian cancer. A previous study reported 
that even after the NCI Clinical Announcement, < 50% of eligi-
ble patients received IP chemotherapy (21), potentially because 
of various concerns including increased toxicity, multiday sche-
duling, and lack of familiarity with catheter placement and IP 
drug administration. Although a question remains as to wheth-
er a course of 6 IP treatments is optimal, only 42% of patients in 
the randomized GOG 172 trial, that compared IP and IV che-
motherapy, received all 6 cycles of the assigned IP therapy due 
Fig. 2. Comparison of survival outcomes between IP and IV chemotherapy groups. (A) PFS according to treatment intention in patients with advanced EOC treated with IP or IV 
chemotherapy. (B) OS according to treatment intention in patients with advanced EOC treated with IP or IV chemotherapy. 
IP = intraperitoneal, IV = intravenous, PFS = progression-free survival, EOC = epithelial ovarian cancer, OS = overall survival.
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Fig. 3. Comparison of survival outcomes between cisplatin-based and carboplatin-based IP chemotherapy subgroups. (A) PFS according to treatment intention in patients with 
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IP = intraperitoneal, IV = intravenous, PFS = progression-free survival, EOC = epithelial ovarian cancer, OS = overall survival.
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Table 4. Comparison of the present IP chemotherapy results with those of other randomized/non-randomized trials
Studies Chemotherapy regimen
Completion rate of the 
intended 6 cycles, %
CR rate, %
Negative sec-
ond look, %
Median PFS Median OS
Carboplatin-based IP chemotherapy
Present study IP carboplatin (AUC 5, D1), 
IV paclitaxel (175 mg/m2, D2),
IP paclitaxel (60 mg/m2, D8)
82.4 90.5 NA 21 52
Fujiwara et al. (10) IP carboplatin (AUC 6, D1), 
IV paclitaxel (175 mg/m2, D1)
84.6 83.3 NA 25 NA
Bouchard-Fortier et al. (14) IP carboplatin (AUC 6, D1), 
IV paclitaxel (135 mg/m2, D1)
60.9 NA NA 25.5 85.3
Cisplatin-based IP chemotherapy
Present study IV paclitaxel (135 mg/m2, D1), 
IP cisplatin (100 mg/m2, D2),
IP paclitaxel (60 mg/m2, D8)
50 81.3 NA 25 96
Alberts et al. (GOG 104) (5) IP cisplatin (100 mg/m2, D1), 
IV cyclophosphamide (600 mg/m2, D1)
58 NA 47 NA 49
Markman et al. (GOG 114) (6) 2 courses IV carboplatin (AUC 9) then:
IV paclitaxel (135 mg/m2, D1), 
IP cisplatin (100 mg/m2, D2)
71 NA NA 27.6 63.2
Armstrong et al. (GOG 172) (7) IV paclitaxel (135 mg/m2, D1), 
IP cisplatin (100 mg/m2, D2),
IP paclitaxel (60 mg/m2, D8)
42 NA 57 24.3 65.6
IP = intraperitoneal, CR = clinical response, PFS = progression-free survival, OS = overall survival, IV = intravenous, AUC = area under curve, NA = not available, GOG = Gyn-
ecologic Oncology Group.
to intolerable toxic effects such as catheter-related complica-
tions; instead, a median of 3 cycles was delivered (7). Ultimate-
ly, when making decisions about the type of adjuvant treatment, 
doctors and patients should be empowered to consider conve-
nience, potential toxicities, and quality of life in addition to the 
possible survival benefit (22).
 To reduce the toxicities associated with cisplatin-based IP 
chemotherapy, some centers have adopted carboplatin-based 
IP regimens. Table 4 lists the results of carboplatin- and cisplat-
in-based IP chemotherapy in other randomized/non-random-
ized trials. In the present study, 83.3% of patients who under-
went carboplatin-based chemotherapy completed the intend-
ed 6 cycles. Furthermore, 19 (90.5%) of the 21 patients had a 
complete response, and 2 had a partial response. Additionally, 
the median PFS was 20 months and the median OS was 52 mon-
ths. In a previous study of IP carboplatin with IV paclitaxel in 
patients with suboptimal residual EOC, the response rate was 
83.3% and the median PFS was 25 months; median OS had not 
been reached (12). A more favorable median OS was reported 
in another study of carboplatin-based IP chemotherapy, with 
smaller amounts of chemotherapeutic agent administered (14). 
However, the reported survival was based on actuarial data, 
limiting comparisons. The relatively lower median PFS and OS 
in the present study are partially due to the inclusion of patients 
whose cytoreduction was suboptimal: Because an IP chemo-
therapeutic agent penetrates to a depth of 2.0–2.5 mm, it is im-
portant that no gross residual disease is present before admin-
istration of IP chemotherapy (23).
 The oncologic outcomes of 3 studies on IP chemotherapy by 
the GOG, that compared IP with IV cisplatin administration, are 
also shown in Table 4. In the phase III GOG 104 trial that com-
pared either 100 mg/m2 IP or IV cisplatin administered with IV 
cyclophosphamide (5), the median survival was significantly 
longer in the group treated with IP (49 months) than in the group 
treated with IV (41 months) cisplatin. The recently published 
phase III GOG 172 trial showed that IP therapy with cisplatin 
and paclitaxel was associated with longer survival in stage III 
patients who underwent optimal cytoreduction, compared with 
the IV chemotherapy group (median PFS of 18.3 and 28.3 months 
in the IV and IP chemotherapy groups, respectively, P = 0.050; 
median OS of 65.6 and 49.7 months, respectively, P = 0.030) (7).
 Although our data suggest the feasibility of carboplatin-based 
IP chemotherapy, without sacrificing patient survival, this in-
terpretation should be approached with caution. The retrospec-
tive nature of this study and small sample size might have re-
sulted in selection bias regarding patient recruitment and may 
have limited the study’s statistical power; our study was not pow-
ered to detect differences in survival. Moreover, the choice of 
carboplatin or cisplatin was not randomized or based on clear 
criteria but on the discretion of each gynecologic oncologist. 
The therapeutic effects of carboplatin-based IP chemotherapy 
should be further evaluated through a large randomized com-
parison study with cisplatin-based IP chemotherapy.
 IP chemotherapy could gain widespread acceptance if the 
associated problems of drug-related toxicity are resolved. In ad-
dition, it is reasonable to substitute carboplatin—a less toxic, 
better-tolerated platinum agent—for cisplatin, particularly in 
patients with severe cisplatin-associated toxicity. Given the po-
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tential advantages of carboplatin-based IP chemotherapy, its 
use could positively impact the therapeutic strategy for patients 
with EOC. However, even though there was no statistical signif-
icance in our cohort, the Kaplan-Meier curve seemed to indi-
cate relatively better outcome in cisplatin-based IP chemother-
apy group, compared with patients receiving carboplatin-based 
IP chemotherapy or IV chemotherapy. We deemed that if the 
size of the cohort is large enough, significant difference might 
be observed.
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